Xi-ChunHuXi-ChunHuFudanUniversityShanghaiCancerQ&ClosingZe-FeiJiang Venue:No.2MeetingRoom,2ndFloor,XiamenInternationalConferenceCenterHoCo-chair:AgnèsBuzyn JieHe赫捷 Ding-WeiYe葉定偉 OpeningRemarks esandchallengesoftheCancerControlnsinAgnèsBuzyn InstitutNationalduCancer,France ResearchandfuturedevelopmentofgastriccancerJia-FuJi季加孚 Q&A Thechallengeofcancerpreventionandhighqualitycancercare--Theexampleof InstitutNationalduCancer, RecentDevelopmentandInnovationsinSurgicalTreatmentforLiverFengShen沈鋒 EasternHepatobiliarySurgeryHospital, Q&A Iscancerasurgicaldisease?Theexampleoflungcancer:mythsandDominiqueH.Grunenwald UniversityofParisVI,France ’sroleintheglobalwaragainstlungcancerTonyMok莫樹(shù)錦 TheUniversityofHongKong, Q&A Medicalinnovationsforcancercarein GlobalHarmonizationofHCCEtiology–LessonsfromEastAnn-LiiCheng鄭安理 CollegeofMedicine,University, Q&A Closing：郭軍 梁軍 HowtocombinesurgeryandsystemictreatmentforadvancedCharlesM.Balch UniversityofTexasSouthwesternMedicalCenter,USA What’snewin2015 melanomaguidelinesDanielCoit MemorialSloan-KetteringCancerCenter,USA NewTrendofMelanomaImmunotherapy郭軍 交流（OralPresentations ysisofretinopathyassociatedwithhighdosesofinterferonα-2btherapyinpatientswithmelanomasoftheskin Cancercenterthefristhospitalofjilin Clinicalresponse,progression- survival(PFS),andsafetyinpatients(pts)withadvancedmelanoma(MEL)receivingnivolumab(NIVO)combinedwithipilimumab(IPI)vsIPImonotherapyinCheckMate069studyChesneyJason UniversityofLouisville,JGrahamBrownCancerCenter,USA AphaseIIstudyofEverolimusforadvancedmelanomapatientswithmTORL.Si PekingUniversitySchoolofOncologyBeijingCancerHospital 連 Safetyprofileofnivolumab(NIVO)inpatients(pts)withadvancedmelanoma(MEL):apooled ChesneyJason UniversityofLouisville,JGrahamBrownCancerCenter,USA EfficacyofHigh-doseAdjuvantInterferonTherapyinHigh-riskMelanoma王 TargetedTherapyof ManagementofMelanomain Currentstatusofmelanomasurgeryin 病例討論-1（Paneldiscussionofcasereport-1）：：CharlesM. Daniel 范 討論：SurgeryandAdjuvant：CharlesM. Daniel 宋 吳 討論：SpecialmelanomasandsystemicSubject：BIGDataandItsImpactonCancerResearchandCancerVenue：1EMeetingRoom,1stFloor,XiamenInternationalConferenceCo-chair：DingYu于 MartinJ. CancerLinQTMfromASCO:EnhancingCancerDiagnosisand AmericanSocietyofClinicalOncology(ASCO), ProjectDataSphere?fromtheCEORoundtableonCancer:APortaltoMartinJ.Murphy CEORoundtableonCancer,USA BigData-thehopeofprecisionmedicineinthecomingfutureLinQiu邱林 HarbinInstituteofHematology&Oncology, CreatingnewparadigmstospeeddrugdevelopmentSusanBates ColumbiaUniversityMedicalCenter,USA DatacreatewondersXue-XingWang王學(xué)興 SinyooInformationTechnology, PanelDiscussion:Howcanbigdatabemorepowerfulandbenefitpublic?Allpesenting：楊林 李勇 病例引導(dǎo)發(fā)言：王暢 黃華 趙 ：袁 病例引導(dǎo)發(fā)言：劉 PS評(píng)分差或伴有相對(duì)癥的晚期胃癌化療策略邱萌 郭 朱 吉林大學(xué)聯(lián)誼醫(yī)：陸 陳 王征 ALK與EGFR突變共同陽(yáng)性的臨床數(shù)據(jù)與治療經(jīng)驗(yàn) 從IPASS到PROFILE1014--展望NSCLC化治療的發(fā) ：秦叔逵陳敏山08:30~09:00GhassanK.Abou-AlfaMemorialSloan-KetteringCancerCenter,交流（OralPresentations09:00~09:10EvaluationofthefrequencyofMETExpressionandAmplificationinHepatocellularCarcinomaPatientsandtheirassociationwithsurvivalFanJiaZhongshanHospital,FudanUniversity EileenM. MemorialSloan-KetteringCancerCenter,交流（OralPresentations Safetyandefficacyoffirst-linetepotinib(MSC J)inaphaseIbtrialinAsianpatientswithadvancedhepatocellularcancerQin 81Hospital 交流（OralPresentations First-linetepotinib(MSC J),anoralc-Metinhibitor,versussorafenibinAsianpatientswithadvancedHCC:phaseIItrialQin 81Hospitalof Circulatingtumorcellsearlypredictprognosisofhepatocellularcarcinomatreatedwithtransarterialchemoembolization:aprospectivestudyZhou FudanUniversityZhongshan 交流（OralPresentations (Thesymposiumonguidelinesandpracticesofdiagnosisandtreatmentinpancreaticcancer)：王理偉 ：郝繼 王儉 交流（OralPresentations：劉寶 Metabolictumorburden:anewpromisingwaytoreachprecise treatmentinPDAC PancreaticCancerInstitute,FudanUniversity/,University/DepartmentofPancreaticandHepatobiliarySurgeryshanghaiCancerCenter Anopen-label,randomized,multicenterstudyofS-1vsGemcitabineinpatientwithadvancedpancreaticcancer TheAffiliatedHospitalofMilitaryMedical ：陳汝 張 張 ：徐建 討論嘉賓：陳 劉秀峰劉天舒袁 ：吳令 周 周 王 交流（OralPresentations Clinicalcharacteristicsofmonodermal tomas:an ysisofalargeseriesof52casesYangBai ObstetricsandGynecologyHospitalofFudanUniversity PrimaryMalignantMelanomaoftheCervix:ARetrospectiveClinicalStudyof14 CancerHospitalofPekingUnionMedicalCollegeandAcademyofMedical TheroleofpostoperativeadjuvanttreatmentinstageIB2/IIA2cervicalcancerpatientswithnopathologicalriskfactorafterneo-adjuvanttreatmentfollowedbyradicalsurgery李 175FIGOIIB期宮頸癌患者術(shù)前新輔助治療療效分析及術(shù)后病理分型對(duì)預(yù)王 大學(xué)醫(yī) 謝宇 第四附屬二院唐都醫(yī)院：李 早期頸癌手術(shù)的QM分期的腹腔鏡手術(shù)應(yīng)用李力 婁 ：李軍 UniversityofHongKong, 中國(guó)大學(xué)附設(shè)醫(yī)院中 B ：王華 中國(guó)彌漫大B細(xì)胞淋巴瘤的治療現(xiàn)狀 B （ResearchPaperPreparationandJournal《臨床腫瘤學(xué)》、《醫(yī)學(xué)會(huì)?腫瘤學(xué)》和《胸部腫瘤學(xué)》：管忠震 陳功 JThoracOncol攻略--青年醫(yī)生運(yùn)用單癌種領(lǐng)域開(kāi)啟科研 HowtogetpublishedinJClinAssociateEditorofJClinOncol Bigdataintopmedicaljournals:tativebiologyforreproducibleresearchandpublishingwithintegrityYuShyr LancetLancet：李 Gettingpublishedinhigh-impactjournals:InsightsfromanDavid 王輝 Publishinghigh-impactpapers:thekeytobeingnoticed ：蔡三軍 PNinoncologycancerpatients:fromsupporttoAlessandroLaviano 章 ：唐平章 TargetTherapyinHNSCC:EGFRopportunitiesinthe Center